
Minghui Pharma announces oncology agreement worth $185 M with Qilu Pharma in Greater China
Minghui Pharma announces oncology agreement worth $185 M with Qilu Pharma in Greater China May 10, 2025 | Saturday | News MHB088C is an innovative B7-H3-targeted antibody-drug conjugate (ADC) developed by Minghui Pharma image credit- shutterstock Minghui …